...
首页> 外文期刊>Seminars in Oncology >ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
【24h】

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

机译:ZD1839是一种选择性的表皮生长因子受体酪氨酸激酶抑制剂,单独使用,并与放射和化学疗法结合使用,可作为非小细胞肺癌的新治疗策略。

获取原文
获取原文并翻译 | 示例
           

摘要

The epidermal growth factor receptor is overexpressed in a majority of non-small cell lung cancers and has been associated with a poor prognosis. Preclinical studies have shown that ZD1839, an oral anilinoquinazoline, targets the epidermal growth factor receptor-associated tyrosine kinase, reversibly inhibiting critical downstream signaling and resulting in cancer cell growth arrest. Potent antitumor effects have been observed in human lung tumor xenograft models. Preclinical studies have shown additive to synergistic effects when ZD1839 is combined with radiation or chemotherapy in colon, head and neck, and non-small cell lung cancers. Phase I clinical trials have shown modest dose-related toxicity, and antitumor activity has been reported in a variety of malignancies including lung cancer. Future studies will certainly combine ZD1839 with chemotherapy or radiation. ZD1839 also may be effective as a chemoprevention agent because premalignant lesions often overexpress epidermal growth factor receptor.
机译:在大多数非小细胞肺癌中,表皮生长因子受体过表达,并且与不良预后有关。临床前研究表明,口服苯胺基喹唑啉ZD1839靶向表皮生长因子受体相关的酪氨酸激酶,可逆地抑制关键的下游信号传导并导致癌细胞生长停滞。在人肺肿瘤异种移植模型中已观察到有效的抗肿瘤作用。临床前研究表明,在结肠癌,头颈癌和非小细胞肺癌中,将ZD1839与放疗或化学疗法联合使用可产生协同作用。一期临床试验已显示出适度的剂量相关毒性,并且已报道了包括肺癌在内的多种恶性肿瘤的抗肿瘤活性。未来的研究肯定会将ZD1839与化学疗法或放射疗法相结合。 ZD1839也可能作为化学预防剂有效,因为恶变前病变通常会过表达表皮生长因子受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号